In the current study, CH treatment significantly (p < 0.05) suppressed the expression of NF-κB and iNOS genes, which contributed to the significantly (p < 0.05) lower NO level in the tumour of CH-treated mice compared to the untreated 4T1-challenged mice. The gene discussed is NOS2; the disease is cyclic hematopoiesis.